Literature DB >> 21604087

Two X-linked chronic granulomatous disease patients with unusual NADPH oxidase properties.

Baruch Wolach1, Arnon Broides, Tal Zeeli, Ronit Gavrieli, Martin de Boer, Karin van Leeuwen, Jacov Levy, Dirk Roos.   

Abstract

BACKGROUND: Chronic granulomatous disease (CGD) is an immune deficiency syndrome caused by defects in the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, the enzyme that generates reactive oxygen species (ROS) in phagocytizing leukocytes. This study evaluates the NADPH oxidase capacity in two X-linked CGD patients with mutations in gp91(phox) that alter the regions in this membrane-bound NADPH oxidase component involved in docking of the cytosolic component p47(phox).
MATERIALS AND METHODS: Hydrogen peroxide and superoxide generation, bactericidal activity, and NADPH oxidase protein expression by the patients' neutrophils were measured, and genetic analysis was performed.
RESULTS: We report two patients, each with a novel missense mutation in CYBB, the gene that encodes gp91(phox). Surprisingly, neutrophils from these patients showed total absence of superoxide production, although they retained 13-30% of the hydrogen peroxide production capability. We speculate that this is due to direct electron transfer from flavin adenine dinucleotide (FAD) in gp91(phox) to oxygen, leading to inefficient hydrogen peroxide formation instead of efficient superoxide production.
CONCLUSIONS: X-linked CGD patients with mutations that alter the gp91(phox) protein in regions involved in docking of the cytosolic NADPH oxidase component p47(phox) may have higher than expected hydrogen peroxide generation capability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21604087     DOI: 10.1007/s10875-011-9537-3

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  24 in total

1.  Characterization of two monoclonal antibodies against cytochrome b558 of human neutrophils.

Authors:  A J Verhoeven; B G Bolscher; L J Meerhof; R van Zwieten; J Keijer; R S Weening; D Roos
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease.

Authors:  S J Vowells; T A Fleisher; S Sekhsaria; D W Alling; T E Maguire; H L Malech
Journal:  J Pediatr       Date:  1996-01       Impact factor: 4.406

4.  Molecular and functional characterization of a new X-linked chronic granulomatous disease variant (X91+) case with a double missense mutation in the cytosolic gp91phox C-terminal tail.

Authors:  Marie José Stasia; Bernard Lardy; Andres Maturana; Pascale Rousseau; Cécile Martel; Pierre Bordigoni; Nicolas Demaurex; Françoise Morel
Journal:  Biochim Biophys Acta       Date:  2002-04-24

5.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

6.  Functional analysis of two-amino acid substitutions in gp91 phox in a patient with X-linked flavocytochrome b558-positive chronic granulomatous disease by means of transgenic PLB-985 cells.

Authors:  Clara Bionda; Xing Jun Li; Robin van Bruggen; Michel Eppink; Dirk Roos; Françoise Morel; Marie-José Stasia
Journal:  Hum Genet       Date:  2004-08-24       Impact factor: 4.132

7.  Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients.

Authors:  Baruch Wolach; Ronit Gavrieli; Martin de Boer; Giora Gottesman; Josef Ben-Ari; Menachem Rottem; Yechiel Schlesinger; Galia Grisaru-Soen; Amos Etzioni; Dirk Roos
Journal:  Clin Immunol       Date:  2008-08-16       Impact factor: 3.969

8.  A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases.

Authors:  M Zhou; Z Diwu; N Panchuk-Voloshina; R P Haugland
Journal:  Anal Biochem       Date:  1997-11-15       Impact factor: 3.365

9.  Biosynthetic human GM-CSF modulates the number and affinity of neutrophil f-Met-Leu-Phe receptors.

Authors:  R H Weisbart; D W Golde; J C Gasson
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

Review 10.  Activation and assembly of the NADPH oxidase: a structural perspective.

Authors:  Yvonne Groemping; Katrin Rittinger
Journal:  Biochem J       Date:  2005-03-15       Impact factor: 3.857

View more
  3 in total

1.  Late diagnosis of chronic granulomatous disease.

Authors:  T Barkai; R Somech; A Broides; R Gavrieli; B Wolach; N Marcus; D Hagin; T Stauber
Journal:  Clin Exp Immunol       Date:  2020-07-13       Impact factor: 4.330

2.  Evidence for bistable bacteria-neutrophil interaction and its clinical implications.

Authors:  Roy Malka; Baruch Wolach; Ronit Gavrieli; Eliezer Shochat; Vered Rom-Kedar
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

3.  Variant Type X91+ Chronic Granulomatous Disease: Clinical and Molecular Characterization in a Chinese Cohort.

Authors:  Bijun Sun; Zeyu Zhu; Xiaoying Hui; Jinqiao Sun; Wenjie Wang; Wenjing Ying; Qinhua Zhou; Haili Yao; Jia Hou; Xiaochuan Wang
Journal:  J Clin Immunol       Date:  2022-07-07       Impact factor: 8.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.